1. Home
  2. TIL vs ATYR Comparison

TIL vs ATYR Comparison

Compare TIL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$8.73

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.98

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIL
ATYR
Founded
2018
2005
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.7M
69.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TIL
ATYR
Price
$8.73
$0.98
Analyst Decision
Buy
Hold
Analyst Count
4
8
Target Price
$125.00
$4.20
AVG Volume (30 Days)
69.8K
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,728.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$0.64
52 Week High
$42.79
$7.29

Technical Indicators

Market Signals
Indicator
TIL
ATYR
Relative Strength Index (RSI) 59.35 64.06
Support Level $7.51 $0.82
Resistance Level $7.87 $0.94
Average True Range (ATR) 0.41 0.10
MACD 0.27 0.01
Stochastic Oscillator 91.03 84.89

Price Performance

Historical Comparison
TIL
ATYR

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: